De klinische relevantie van cribriforme en intraductale prostaatkanker in diagnostische naaldbiopten

Charlotte F. Kweldam; Intan P. Kümmerlin; Daan Nieboer; Esther I. Verhoef; Ewout W. Steyerberg; Luca Incrocci; Chris H. Bangma; Theodorus H. van der Kwast; Monique J. Roobol; Geert J. van Leenders

doi:10.1007/s13629-016-0163-y

De klinische relevantie van cribriforme en intraductale prostaatkanker in diagnostische naaldbiopten

Translated title of the contribution: The clinical relevance of cribriform and intraductal prostate cancer in diagnostic needle biopsies

Charlotte F. Kweldam^*
, Intan P. Kümmerlin
, Daan Nieboer
, Esther I. Verhoef
, Ewout W. Steyerberg
, Luca Incrocci
, Chris H. Bangma
, Theodorus H. van der Kwast
, Monique J. Roobol
, Geert J. van Leenders

^*Corresponding author for this work

University Health Network

Research output: Contribution to journal › Article › Academic › peer-review

1 Citation (Scopus)

41 Downloads (Pure)

Abstract

Cribriform and intraductal prostate cancer are both associated with an adverse outcome after radical prostatectomy. We included all patients with prostate cancer from the first screening round of the European Randomized Study of Screening for Prostate Cancer (ERSPC). All available slides were revised and scored for presence of cribriform and/or intraductal prostate cancer. Outcome measurements were biochemical recurrence and disease-specific survival. In total, 486 patients had Gleason score (GS) 6 (47%) and 545 GS ≥7 (53%). The disease-specific survival and biochemical-recurrence-free survival of CR/IDC⁻-GS3+4 patients did not differ significantly from those with GS 6, while patients with CR/IDC⁺-GS3+4-patients had a significant poorer outcome. Conclusion: The presence of cribriform and intraductal growth in prostate cancer, is a strong clinical prognostic marker with potential. The use of this variable in a clinical setting could contribute to reducing overtreatment of prostate cancer.

Translated title of the contribution	The clinical relevance of cribriform and intraductal prostate cancer in diagnostic needle biopsies
Original language	Dutch
Pages (from-to)	168-177
Number of pages	10
Journal	Tijdschrift voor Urologie
Volume	7
Issue number	8
DOIs	https://doi.org/10.1007/s13629-016-0163-y
Publication status	Published - Dec 2017

Bibliographical note

Publisher Copyright:
© 2017, The Author(s).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1007/s13629-016-0163-yLicence: CC BY

De klinische relevantie van cribriforme en intraductale prostaatkanker in diagnostische naaldbioptenFinal published version, 554 KBLicence: CC BY

Cite this

@article{3dbe35cb7c354206b22ea1032b5ac1d3,

title = "De klinische relevantie van cribriforme en intraductale prostaatkanker in diagnostische naaldbiopten",

abstract = "Cribriform and intraductal prostate cancer are both associated with an adverse outcome after radical prostatectomy. We included all patients with prostate cancer from the first screening round of the European Randomized Study of Screening for Prostate Cancer (ERSPC). All available slides were revised and scored for presence of cribriform and/or intraductal prostate cancer. Outcome measurements were biochemical recurrence and disease-specific survival. In total, 486 patients had Gleason score (GS) 6 (47\%) and 545 GS ≥7 (53\%). The disease-specific survival and biochemical-recurrence-free survival of CR/IDC−-GS3+4 patients did not differ significantly from those with GS 6, while patients with CR/IDC+-GS3+4-patients had a significant poorer outcome. Conclusion: The presence of cribriform and intraductal growth in prostate cancer, is a strong clinical prognostic marker with potential. The use of this variable in a clinical setting could contribute to reducing overtreatment of prostate cancer.",

author = "Kweldam, \{Charlotte F.\} and K{\"u}mmerlin, \{Intan P.\} and Daan Nieboer and Verhoef, \{Esther I.\} and Steyerberg, \{Ewout W.\} and Luca Incrocci and Bangma, \{Chris H.\} and \{van der Kwast\}, \{Theodorus H.\} and Roobol, \{Monique J.\} and \{van Leenders\}, \{Geert J.\}",

note = "Publisher Copyright: {\textcopyright} 2017, The Author(s).",

year = "2017",

month = dec,

doi = "10.1007/s13629-016-0163-y",

language = "Dutch",

volume = "7",

pages = "168--177",

journal = "Tijdschrift voor Urologie",

issn = "2211-3037",

publisher = "Springer Science+Business Media",

number = "8",

}

TY - JOUR

T1 - De klinische relevantie van cribriforme en intraductale prostaatkanker in diagnostische naaldbiopten

AU - Kweldam, Charlotte F.

AU - Kümmerlin, Intan P.

AU - Nieboer, Daan

AU - Verhoef, Esther I.

AU - Steyerberg, Ewout W.

AU - Incrocci, Luca

AU - Bangma, Chris H.

AU - van der Kwast, Theodorus H.

AU - Roobol, Monique J.

AU - van Leenders, Geert J.

PY - 2017/12

Y1 - 2017/12

N2 - Cribriform and intraductal prostate cancer are both associated with an adverse outcome after radical prostatectomy. We included all patients with prostate cancer from the first screening round of the European Randomized Study of Screening for Prostate Cancer (ERSPC). All available slides were revised and scored for presence of cribriform and/or intraductal prostate cancer. Outcome measurements were biochemical recurrence and disease-specific survival. In total, 486 patients had Gleason score (GS) 6 (47%) and 545 GS ≥7 (53%). The disease-specific survival and biochemical-recurrence-free survival of CR/IDC−-GS3+4 patients did not differ significantly from those with GS 6, while patients with CR/IDC+-GS3+4-patients had a significant poorer outcome. Conclusion: The presence of cribriform and intraductal growth in prostate cancer, is a strong clinical prognostic marker with potential. The use of this variable in a clinical setting could contribute to reducing overtreatment of prostate cancer.

AB - Cribriform and intraductal prostate cancer are both associated with an adverse outcome after radical prostatectomy. We included all patients with prostate cancer from the first screening round of the European Randomized Study of Screening for Prostate Cancer (ERSPC). All available slides were revised and scored for presence of cribriform and/or intraductal prostate cancer. Outcome measurements were biochemical recurrence and disease-specific survival. In total, 486 patients had Gleason score (GS) 6 (47%) and 545 GS ≥7 (53%). The disease-specific survival and biochemical-recurrence-free survival of CR/IDC−-GS3+4 patients did not differ significantly from those with GS 6, while patients with CR/IDC+-GS3+4-patients had a significant poorer outcome. Conclusion: The presence of cribriform and intraductal growth in prostate cancer, is a strong clinical prognostic marker with potential. The use of this variable in a clinical setting could contribute to reducing overtreatment of prostate cancer.

UR - https://www.scopus.com/pages/publications/85037116976

U2 - 10.1007/s13629-016-0163-y

DO - 10.1007/s13629-016-0163-y

M3 - Article

AN - SCOPUS:85037116976

SN - 2211-3037

VL - 7

SP - 168

EP - 177

JO - Tijdschrift voor Urologie

JF - Tijdschrift voor Urologie

IS - 8

ER -

De klinische relevantie van cribriforme en intraductale prostaatkanker in diagnostische naaldbiopten

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this